UCIBIO Director Paula Videira finalist for the 2026 European Inventor Award
Paula Videira, Director of UCIBIO and leader of the Glycoimmunology Research Lab at UCIBIO-NOVA FCT, has been selected as a finalist for the prestigious 2026 European Inventor Award. The nomination recognizes the development of L2A5, a breakthrough antibody that identifies cancer-specific molecular signatures with unprecedented precision.
UCIBIO researchers uncover 12 years of genomic evolution in a high-priority hospital pathogen
A study led by the Bact_Drugs Lab at UCIBIO-Porto, published in Genome Medicine, reveals how Enterococcus faecium uses "linear plasmids" and antimicrobial peptides to outcompete rivals and evade infection control.
Pioneering Sustainable Health: UCIBIO partners in the new NOVA_i4SF Centre of Excellence
NOVA FCT has secured a remarkable achievement by winning the leadership of the NOVA Institute For A Sustainable Future (NOVA_i4SF). This project was selected under the highly competitive European Commission Teaming for Excellence program, emerging as one of only six Portuguese projects approved among a select group of 19 funded across Europe.
UCIBIO researchers develop method to accelerate study of major agricultural pathogen
A team of researchers from the MolMicro of Bacterial Pathogens lab at UCIBIO - NOVA FCT has developed a new laboratory culture medium that enables the fast and effective in vitro growth of Xylella fastidiosa.